Envestnet Asset Management Inc. Sells 1,539 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Envestnet Asset Management Inc. lessened its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,297 shares of the biopharmaceutical company’s stock after selling 1,539 shares during the period. Envestnet Asset Management Inc. owned approximately 0.06% of Xenon Pharmaceuticals worth $1,854,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Prudential Financial Inc. increased its stake in Xenon Pharmaceuticals by 177.7% in the fourth quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company’s stock valued at $1,529,000 after purchasing an additional 24,956 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after buying an additional 905,129 shares during the period. Barclays PLC boosted its holdings in shares of Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after buying an additional 13,903 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Xenon Pharmaceuticals by 12.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company’s stock valued at $9,350,000 after buying an additional 26,235 shares during the period. Finally, Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $101,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $37.62 on Monday. The company has a market cap of $2.88 billion, a PE ratio of -13.34 and a beta of 1.21. The firm has a 50-day moving average of $34.80 and a 200-day moving average of $38.66. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05. Analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on XENE shares. StockNews.com upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $56.78.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.